Luye Licenses China Rights To Cancer Drug From Hanmi Pharma
This article was originally published in PharmAsia News
Executive Summary
Luye Pharma Group has licensed Hanmi Pharmaceutical's poziotinib, a pan-HER inhibitor to treat cancer, for exclusive rights in China.
You may also be interested in...
Should Pharma Be Concerned About Cooling China-Korea Ties?
Despite regional defense policy concerns that have prompted broad moves to limit economic exchanges between China and South Korea, which could also potentially affect ever expanding healthcare collaborations between the two countries, the pharma sector impact so far appears to be limited.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.